A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
Status:
Withdrawn
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on
liver health and liver fat content in patients with T2DM who also have Nonalcoholic
Steatohepatitis (NASH).
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.